Bibliography
- Gao ZG, Jacobson KA. Emerging adenosine receptor agonists. Expert Opin Emerg Drugs 2007;12(3):479-92
- Fredholm BB, IJzerman AP, Jacobson KA, International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors–an update. Pharmacol Rev 2011;63(1):1-34
- Jacobson KA, Gao ZG. Adenosine receptors as therapeutic targets. Nat Rev Drug Discov 2006;5(3):247-64
- Elzein E, Zablocki J. A1 adenosine receptor agonists and their potential therapeutic applications. Expert Opin Investig Drugs 2008;17(12):1901-10
- Cristalli G, Muller CE, Volpini R. Recent developments in adenosine A2A receptor ligands. Handb Exp Pharmacol 2009(193):59-98
- Hasko G, Linden J, Cronstein B, Pacher P. Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat Rev Drug Discov 2008;7(9):759-70
- Koeppen M, Eckle T, Eltzschig HK. Interplay of hypoxia and A2B adenosine receptors in tissue protection. Adv Pharmacol 2011;61:145-86
- Feoktistov I, Biaggioni I. Role of adenosine A2B receptors in inflammation. Adv Pharmacol 2011;61:115-44
- Fishman P, Bar-Yehuda S, Liang BT, Jacobson KA. Pharmacological and therapeutic effects of A3 adenosine receptor agonists. Drug Discov Today; In press
- Clinicaltrials.gov
- Romagnoli R, Baraldi PG, Tabrizi MA, Allosteric enhancers of A1 adenosine receptors: state of the art and new horizons for drug development. Curr Med Chem 2010;17(30):3488-502
- Dhalla AK, Santikul M, Smith M, Antilipolytic activity of a novel partial A1 adenosine receptor agonist devoid of cardiovascular effects: comparison with nicotinic acid. J Pharmacol Exp Ther 2007;321(1):327-33
- Delarue J, Magnan C. Free fatty acids and insulin resistance. Curr Opin Clin Nutr Metab Care 2007;10(2):142-8
- Eckle T, Krahn T, Grenz A, Cardioprotection by ecto-5'-nucleotidase (CD73) and A2B adenosine receptors. Circulation 2007;115(12):1581-90
- Drug-eluting stents for adenosine receptor modulation. US20110189255; 2011
- Du L, Gao ZG, Nithipatikom K, Protection from myocardial ischemia/reperfusion injury by a positive allosteric modulator of the A3 adenosine receptor. J Pharmacol Exp Ther 2011; Epub ahead of print
- Gao ZG, Verzijl D, Zweemer A, Functionally biased modulation of A3 adenosine receptor agonist efficacy and potency by imidazoquinolinamine allosteric enhancers. Biochem Pharmacol 2011;82(6):658-68
- Antonioli L, Fornai M, Colucci R, Regulation of enteric functions by adenosine: pathophysiological and pharmacological implications. Pharmacol Ther 2008;120(3):233-53
- Gessi S, Merighi S, Varani K, The A3 adenosine receptor: an enigmatic player in cell biology. Pharmacol Ther 2008;117(1):123-40
- Xu F, Wu H, Katritch V, Structure of an agonist-bound human A2A adenosine receptor. Science 2011;332(6027):322-7